SEATTLE, WA--(Marketwired - September 25, 2013) - Plandaí Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced that it has executed a letter of intent with a major producer of nutraceutical cold and flu remedies under which all of 2014 estimated production capacity of Phytofare™ Limonoid Glycoside Complex, estimated at 15 tons, will be purchased. The letter of intent is subject to favorable results from a clinical trial which is expected to commence late in 2013.
Plandaí's Phytofare™ Limonoid Glycoside Complex is derived from lemons, utilizing the entire fruit -- pith, peel, pulp and juice -- and is rich in the entire spectrum of 170 phytochemicals including flavonoids, Vitamin C, and limonoid glycosides (antioxidants). Prior clinical investigations of citrus bioflavonoids showed improved wellness benefits in combating allergic and vasomotor rhinitis (common cold). This includes the lowering of chills, feverishness, headache or general aching, nasal stiffness or discharge, sore throat, cough and sputum expectoration.
Roger Duffield, Chairman and Chief Executive Officer of Plandaí Biotechnology, commented, "Over a hundred clinical publications on citrus bioflavonoids demonstrates conclusive evidence of flavonoid efficacy in addressing capillary permeability, alleviating symptoms of the common cold and providing inflammatory relief. We are confident that the higher purity and increased bioavailability of our Phytofare™ Limonoid Glycoside Complex will yield improved results over the earlier studies which lacked the superior bioactive properties of Phytofare™."
Plandaí expects to commence commercial production of Phytofare™ Limonoid Glycoside Complex in June 2014, when the green tea on the Senteeko Estate enters its annual dormant state. The four-month production cycle is anticipated to yield 15 tons of limonoid glycoside powder extract in 2014, which can be sold "as is" or further processed into Pheroid™ emulsions, depending on the customer's specifications. If demand for the Limonoid Glycoside product remains high, production can be increased to 40 tons for 2015.
About Plandaí Biotechnology, Inc.
Plandaí Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandaí Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its patented Phytofare™ extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.
Safe Harbor Statement
The information provided may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Plandaí's ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Plandaí is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.